Oral PH - Pulmonary Arterial Hypertension

365 - Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function

Presentation Number
365
Presenter
Co-Authors

Previous Eposter
358 - Ex-vivo Lung Perfusion - 10 Year Follow-up of the First Performed Double LTX With Marginal Donor Lungs Evaluated Using EVLP

Next Eposters
366 - Rates of Hospitalization Associated with the Use of Aldosterone Receptor Antagonists in Patients with Pulmonary Arterial Hypertension
367 - OPUS Registry: Switching to Macitentan From Other Endothelin Receptor Antagonists (ERAs)
376 - Defining Severe Secondary Antibody Deficiency in Heart and Lung Transplantation
377 - Survival and Outcome in Pediatric Myocarditis - 3 Year Data from the German Multi-center Prospective Myocarditis Registry: “MYKKE”
378 - Acute Decompensated Heart Failure in the Pediatric Population: A Report from the Pediatric Cardiac Critical Care Consortium (PC4)
432 - Hemodynamic Response to Continuous-flow Left Ventricular Assist Device Ramp Test and Volume Loading Predicts Successful Weaning from the Device Support
442 - Human Leukocyte Compatibility and Heart Transplant Survival Using a Validated Matching Algorithm
446 - Sarcopenia of the Psoas Muscles Predicts Survival Following Lung Transplantation
453 - Leptin Modifies the Impact of BMI on Heart Failure Progression: The Obesity Paradox Unraveling
454 - NT-proBNP Levels Are Reduced Following Treatment With Growth Hormone in Chronic Heart Failure Due to Ischemic Heart Disease. A Randomized Double Blind Placebo Controlled Trial